What is Chardan Capital’s Forecast for OCUL FY2025 Earnings?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Research analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Ocular Therapeutix in a research report issued on Wednesday, October 15th. Chardan Capital analyst D. Gataulin expects that the biopharmaceutical company will earn ($1.45) per share for the year. Chardan Capital has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. Chardan Capital also issued estimates for Ocular Therapeutix’s FY2026 earnings at ($0.99) EPS.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The firm had revenue of $13.46 million for the quarter, compared to analyst estimates of $13.12 million. During the same period in the prior year, the company posted ($0.26) EPS. The firm’s quarterly revenue was down 17.7% compared to the same quarter last year.

OCUL has been the topic of a number of other research reports. Needham & Company LLC increased their price target on Ocular Therapeutix from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. HC Wainwright increased their price target on Ocular Therapeutix from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Zacks Research raised Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 2nd. Piper Sandler increased their price target on Ocular Therapeutix from $21.00 to $31.00 and gave the company an “overweight” rating in a research note on Friday, October 3rd. Finally, Scotiabank cut their price target on Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating on the stock in a research note on Wednesday, August 6th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.63.

Ocular Therapeutix Stock Performance

OCUL stock opened at $11.84 on Monday. The business’s fifty day moving average is $12.24 and its 200-day moving average is $10.05. The company has a quick ratio of 10.02, a current ratio of 10.10 and a debt-to-equity ratio of 0.23. The company has a market cap of $2.06 billion, a P/E ratio of -9.25 and a beta of 1.45. Ocular Therapeutix has a twelve month low of $5.78 and a twelve month high of $13.85.

Institutional Trading of Ocular Therapeutix

A number of large investors have recently made changes to their positions in the company. Union Bancaire Privee UBP SA bought a new stake in shares of Ocular Therapeutix in the 3rd quarter valued at $298,000. Osaic Holdings Inc. increased its holdings in Ocular Therapeutix by 19,194.3% during the 2nd quarter. Osaic Holdings Inc. now owns 67,530 shares of the biopharmaceutical company’s stock worth $627,000 after purchasing an additional 67,180 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Ocular Therapeutix by 96.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 61,995 shares of the biopharmaceutical company’s stock worth $575,000 after purchasing an additional 30,460 shares in the last quarter. Marex Group plc bought a new position in Ocular Therapeutix during the 2nd quarter worth about $115,000. Finally, Hudson Bay Capital Management LP bought a new position in Ocular Therapeutix during the 2nd quarter worth about $502,000. Institutional investors own 59.21% of the company’s stock.

Insider Activity

In related news, insider Jeffrey S. Heier sold 10,502 shares of the company’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $11.04, for a total value of $115,942.08. Following the completion of the sale, the insider owned 249,409 shares in the company, valued at $2,753,475.36. This represents a 4.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Pravin Dugel sold 21,494 shares of the company’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $12.04, for a total transaction of $258,787.76. Following the completion of the sale, the insider owned 3,227,244 shares of the company’s stock, valued at approximately $38,856,017.76. This represents a 0.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 61,806 shares of company stock worth $727,648 in the last 90 days. Corporate insiders own 2.30% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.